Andrew Woodhead

Computer Science · Physical Sciences

10h-index2.0kcitations45works7.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(12), Heat shock proteins research(7), Monoclonal and Polyclonal Antibodies Research(5), Click Chemistry and Applications(5), Cancer-related Molecular Pathways(4)

Publications45 total

Correction to “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”
Journal of Medicinal Chemistry·2025
Abstract 1627: Switching cell fate from senescence to apoptosis by the combination of a p53 corrector with the MDM2 antagonist ASTX295
Cancer Research·2025
Fragment-to-Lead Medicinal Chemistry Publications in 2023
Journal of Medicinal Chemistry·2025· 16 citedOpen Access
Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function
Nature Communications·2024· 4 citedOpen Access
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design
Structure·2024· 4 citedOpen Access
Meaningful co-production to bring meaningful change: Developing the Allied Health Professionals Dementia Framework for Wales together
Dementia·2024· 1 cited
Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4
Cancer Research·2024
Abstract 7073: Integrating fragment-based crystallographic screening with dTAG-PROTAC degradation and genetic rescue to explore the function of eIF4E
Cancer Research·2024
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
Journal of Medicinal Chemistry·2024· 10 citedOpen Access
Fragment-to-Lead Medicinal Chemistry Publications in 2022
Journal of Medicinal Chemistry·2024· 38 citedOpen Access
Abstract A142: Fragment based discovery of inhibitors of the eIF4E:eIF4G interaction
Molecular Cancer Therapeutics·2023
Abstract A110: Identifying sensitive patient populations for CDK7 inhibitors using cell panel screens and bioinformatic approaches
Molecular Cancer Therapeutics·2023
Abstract A143: Coupling fragment-based screening with targeted protein degradation and genetic rescue to identify and explore the function of a non-canonical pocket on eIF4E
Molecular Cancer Therapeutics·2023
Abstract 3722: Exploring the role of eIF4E in cancer cells with targeted protein degradation
Cancer Research·2023
Fragment-to-Lead Medicinal Chemistry Publications in 2021
Journal of Medicinal Chemistry·2023· 39 citedOpen Access
Masseter muscle rigidity and the role of DNA analysis to confirm malignant hyperthermia susceptibility
Anaesthesia and Intensive Care·2019· 1 citedOpen Access
Identification of novel allosteric inhibitors through fragment-based drug discovery and X-ray crystallography  
Acta Crystallographica Section A Foundations and Advances·2015Open Access
CCDC 1439329: Experimental Crystal Structure Determination
The Cambridge Structural Database·2015Open Access
CCDC 1439330: Experimental Crystal Structure Determination
The Cambridge Structural Database·2015Open Access
page 1 of 3Next →

Frequent Co-authors

Gianni Chessari(19), Christopher W. Murray(14), Maria G. Carr(13), Joseph E. Coyle(11), Brent Graham(11), Miles Congreve(10), M. Vinković(10), Martyn Frederickson(9), Dominic Tisi(8), Rachel McMenamin(8), Puja Pathuri(8), Alison J.‐A. Woolford(7), Lynsey Fazal(7), Sharna J. Rich(7), Harren Jhoti(7), Glyn Williams(7), C. Hamlett(7), Nicola G. Wallis(7), Philip J. Day(6), S. Saalau-Bethell(6)